Intellia Therapeutics (NTLA) recently reported first quarter results showing a net loss of US$96.23 million and basic loss per share of US$0.81, compared with US$114.33 million and US$1.10 a year earlier.

Despite a recent 7 day share price return that declined 7.83% and a 30 day share price return that declined 7.56%, Intellia’s year to date share price return of 36.81% and 1 year total shareholder return of 37.55% suggest momentum has been building around the story. The latest quarter’s narrower loss is likely influencing how investors weigh long term potential against past 3 and 5 year total shareholder return declines of 67.68% and 83.19% respectively.

If Intellia’s recent move has you thinking about where else growth stories could emerge in healthcare, this is a good moment to scan 34 healthcare AI stocks

With analyst targets sitting above the current US$12.60 share price and a smaller quarterly loss on the books, the key question is whether Intellia is still trading at a discount or if markets are already pricing in future growth.

Most Popular Narrative: 52.8% Undervalued

With the most followed narrative pointing to a fair value of $26.70 versus the last close at $12.60, the gap between story and share price is wide.

Improving financial discipline, as evidenced by successful restructuring, declining GAAP operating expenses (~10% reduction YoY), and a robust cash runway into the first half of 2027, enables Intellia to absorb increased R&D investment, advance pipeline expansion, and build out commercial infrastructure without dilutive fundraising, supporting protection of net margins and improving future earnings visibility.

Want to see what kind of revenue ramp, margin shift, and earnings swing are baked into that fair value? The most followed narrative lays out an aggressive trajectory built on rapid top line expansion and a sharp turn toward profitability, with a long term earnings multiple that would usually be associated with mature leaders. Curious which specific financial milestones have to line up for $26.70 to make sense.

Result: Fair Value of $26.70 (UNDERVALUED)

However, sustained high R&D costs with no commercial revenue yet, along with safety and uptake questions around key ATTR and HAE programs, could quickly challenge that undervalued story.

Another Angle on Valuation

The narrative fair value of $26.70 points to a large upside gap. However, Intellia trades on a P/S of 26.6x versus 10.7x for the US Biotechs industry and a fair ratio of 0.1x. That represents a wide premium for a loss making company, so how much valuation risk are you comfortable carrying?

Next Steps

Mixed signals like these can be confusing, so take a closer look at the full picture and decide how it fits your risk appetite by weighing up the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If this kind of deep dive helps clarify Intellia, do not stop here. The next smart move is lining up a watchlist of fresh opportunities before the crowd notices.

• Target potential value opportunities by scanning the 49 high quality undervalued stocks that combine quality fundamentals with pricing that may still be catching up.
• Focus on capital preservation first with the 67 resilient stocks with low risk scores and narrow in on companies that score well on resilience and balance sheet strength.
• Spot future standouts early with the screener containing 21 high quality undiscovered gems that highlight quality businesses many investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.